Analyst Recommendation: Mizuho has maintained an "Outperform" rating for Cencora (NYSE:COR) with a one-year price target average of $345.21/share, indicating a potential upside of 1.13% from its recent closing price.
Fund Sentiment: There are 2,406 funds reporting positions in Cencora, with a 4.07% increase in ownership over the last quarter, although total shares owned by institutions decreased by 1.52%.
Shareholder Activity: Major shareholders like Price T Rowe Associates and Walgreens Boots Alliance have reduced their holdings significantly, while Vanguard Total Stock Market Index Fund has increased its stake.
Market Outlook: The put/call ratio for Cencora is 0.64, suggesting a bullish sentiment among investors regarding the stock's future performance.
COR
$350.32+Infinity%1D
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 346.000
Low
361.00
Averages
393.78
High
417.00
Current: 346.000
Low
361.00
Averages
393.78
High
417.00
Barclays
Overweight
initiated
$400
2025-12-08
Reason
Barclays
Price Target
$400
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of Cencora with an Overweight rating and $400 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Wells Fargo
Overweight
maintain
$354 -> $405
2025-11-11
Reason
Wells Fargo
Price Target
$354 -> $405
2025-11-11
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Cencora to $405 from $354 and keeps an Overweight rating on the shares. The firm says the company reported fairly strong Q4 results and introduced attractive FY26 guidance. Core growth in U.S. Healthcare remains outstanding and absent material deceleration would seem to suggest potential for additional positive estimate revisions, Wells adds.
JPMorgan
NULL -> Overweight
maintain
$344 -> $417
2025-11-11
Reason
JPMorgan
Price Target
$344 -> $417
2025-11-11
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Cencora to $417 from $344 and keeps an Overweight rating on the shares. The firm updated the company's model.
TD Cowen
Buy
maintain
$350 -> $400
2025-11-10
Reason
TD Cowen
Price Target
$350 -> $400
2025-11-10
maintain
Buy
Reason
TD Cowen raised the firm's price target on Cencora to $400 from $350 and keeps a Buy rating on the shares. The firm said they remain confident in the shares following F4Q25 and the introduction of its FY26 guidance where they continue to see upside.
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
